LOUISVILLE, Ky.–(BUSINESS WIRE)– The Supreme Courts decision today to invalidate patents on human genes changes the landscape of Personalized Medicine, making it possible for more patients to benefit from genetic testing while substantially lowering the cost of that testing. PGXLs mission is to advance Personalized Medicine for the improvement of peoples lives, says Dr. Roland Valdes, Jr., President of PGXL Laboratories. Continue reading
Tag Archives: myriad-genetics
Supreme Court To Decide If Human Genes Can Be Patented In Myriad Case
The U.S. Supreme Court agreed to hear, for a second time, a lawsuit challenging patents held by Myriad Genetics on human genes implicated in breast cancer. Continue reading
Privately owned genetic databases may hinder diagnosis and bar the way to the arrival of personalized medicine
Public release date: 31-Oct-2012 [ | E-mail | Share ] Contact: Mary Rice mary.rice@riceconseil.eu European Society of Human Genetics In response to the on-line publication by the European Journal of Human Genetics today (Wednesday) of an article by US researchers led by Dr. Robert Cook-Degan, a former member of the US Office of Technology Assessment, showing that Myriad Genetics, providers of the BRCA1/2 genetic test in the US, has amassed vast quantities of clinical data without sharing it, Professor Martina Cornel, chair of the European Society of Human Genetics’ Professional and Public Policy committee, said: “We are very concerned that such important data is being withheld from those who most need it. Interpreting the variants of unknown significance (VUS) that may be found on analysing the patient’s genome plays an essential part in being able to provide proper counselling and if necessary, preventive or therapeutic guidance. Continue reading
Myriad Genetics Sponsors Cancer Awareness Initiatives in Support of National Hereditary Breast and Ovarian Cancer Week
SALT LAKE CITY, Oct. 3, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc Continue reading
Myriad Presents Variant of Uncertain Significance Rates at European Human Genetics Conference 2012
ZURICH, Switzerland–(BUSINESS WIRE)– Myriad Genetics GmbH announced today that a presentation entitled Current Variant of Uncertain Significance Rates in BRCA 1/2 and Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) Testing, was presented today at the European Human Genetics Conference in Nurnberg, Germany. The study highlights Myriads best-in-class variant classification process and variant of uncertain significance rate. Continue reading
Myriad Genetics Receives the Charles R. Smart Visionary Award From the American Cancer Society(R)
SALT LAKE CITY, June 6, 2012 (GLOBE NEWSWIRE) — Myriad Genetics announced today that the Company is the honorable recipient of the 2012 Charles R. Smart Visionary Award from the American Cancer Society’s Salt Lake City office, a part of the Great West Division. Continue reading
Myriad Genetics to Present at Upcoming Investor Conferences in June
SALT LAKE CITY, May 22, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN – News) announced today that the Company is scheduled to present at two upcoming investor conferences: Both presentations will be available to interested parties via webcast on the investor relations section of Myriad’s website at www.myriad.com. Continue reading
Myriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting
SALT LAKE CITY, May 16, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. Continue reading
Myriad Genetics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
SALT LAKE CITY, May 2, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (MYGN – News) announced today that Peter D Continue reading